VelosBio announces first patient dosed in phase 2 trial of VLS-101 in solid tumours

This article was originally published here

ROR1 is a cell-surface protein that is expressed during embryofetal development but disappears before birth and is usually not expressed on normal cells in children or adults. However,

The post VelosBio announces first patient dosed in phase 2 trial of VLS-101 in solid tumours appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply